These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34713140)

  • 1. The Impact of Digital Therapeutics on Current Health Technology Assessment Frameworks.
    Yan K; Balijepalli C; Druyts E
    Front Digit Health; 2021; 3():667016. PubMed ID: 34713140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
    Ball G; Levine MAH; Thabane L; Tarride JE
    Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies.
    Harricharan S; Curran E; Lin HM; Walton L; Gurjar K; Nguyen K; Forsythe A
    Future Oncol; 2023 Mar; 19(8):603-616. PubMed ID: 37083358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold.
    Griffiths EA; Hendrich JK; Stoddart SD; Walsh SC
    Clinicoecon Outcomes Res; 2015; 7():463-76. PubMed ID: 26366099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobile Safety Alarms Based on GPS Technology in the Care of Older Adults: Systematic Review of Evidence Based on a General Evidence Framework for Digital Health Technologies.
    Ehn M; Richardson MX; Landerdahl Stridsberg S; Redekop K; Wamala-Andersson S
    J Med Internet Res; 2021 Oct; 23(10):e27267. PubMed ID: 34633291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early access for innovative oncology medicines: a different story in each nation.
    Cowling T; Nayakarathna R; Wills AL; Tankala D; Paul Roc N; Barakat S
    J Med Econ; 2023; 26(1):944-953. PubMed ID: 37466223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies.
    Sarri G; Hernandez LG
    J Comp Eff Res; 2024 Sep; 13(9):e240061. PubMed ID: 39132748
    [No Abstract]   [Full Text] [Related]  

  • 10. Success Factors for Scaling Up the Adoption of Digital Therapeutics Towards the Realization of P5 Medicine.
    Prodan A; Deimel L; Ahlqvist J; Birov S; Thiel R; Toivanen M; Kolitsi Z; Kalra D
    Front Med (Lausanne); 2022; 9():854665. PubMed ID: 35492346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
    Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
    Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
    Trouiller JB; Laramée P
    Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health Technology Assessment in Australia: The Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee.
    Kim H; Byrnes J; Goodall S;
    Value Health Reg Issues; 2021 May; 24():6-11. PubMed ID: 33429153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the National Institute for Health and Care Excellence Evidence Standards Framework for Digital Health Technologies in Assessing Mobile-Delivered Technologies for the Self-Management of Type 2 Diabetes Mellitus: Scoping Review.
    Forsyth JR; Chase H; Roberts NW; Armitage LC; Farmer AJ
    JMIR Diabetes; 2021 Feb; 6(1):e23687. PubMed ID: 33591278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
    Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
    Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The extent and quality of qualitative evidence included in health technology assessments: a review of submissions to NICE and CADTH.
    Szabo SM; Hawkins NS; Germeni E
    Int J Technol Assess Health Care; 2023 Dec; 40(1):e6. PubMed ID: 38126273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
    Wang S; Gum D; Merlin T
    Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments.
    Appiah K; Rizzo M; Sarri G; Hernandez L
    J Comp Eff Res; 2024 Feb; 13(2):e230140. PubMed ID: 38174576
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessing the Value of Provider-Facing Digital Health Technologies Used in Chronic Disease Management: Toward a Value Framework Based on Multistakeholder Perceptions.
    Main C; Haig M; Chavez D; Kanavos P
    Med Decis Making; 2024 Jan; 44(1):28-41. PubMed ID: 37882333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines.
    Grigore B; Ciani O; Dams F; Federici C; de Groot S; Möllenkamp M; Rabbe S; Shatrov K; Zemplenyi A; Taylor RS
    Pharmacoeconomics; 2020 Oct; 38(10):1055-1070. PubMed ID: 32572825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.